Donald Trump’s proposed 200% tariff on generic drug imports is less a blow to India’s pharmaceutical industry than a costly gamble that could leave American patients paying the highest price.
U.S. companies, importers and retailers will bear the initial costs which most economists expect to filter through the supply chain as a cost-push inflation.